Facing increasing competition from local drug manufacturers, Novo Nordisk has announced a price reduction of up to 48% for its obesity treatment Wegovy in China. This strategic move, along with recent FDA approval for an orally administered version of Wegovy, aims to alleviate treatment burdens for patients. Despite these initiatives, Novo Nordisk's stock has declined by over 40% in the past year and is not regarded as a popular choice among hedge funds.
“the two biggest drugmakers selling GLP-1s · are · Eli Lilly and Novo Nordisk”
“Novo Nordisk · is pleased that · the Court · upheld the ruling recognising the validity of the semaglutide compound patent”
“Novo Nordisk · employs · about 78,500 people”
“Novo Nordisk · markets products in · around 170 countries”
“Novo Nordisk A/S (NYSE:NVO) · had one-month return · 7.99%”
“Novo Nordisk A/S (NYSE:NVO) · lost shares value · 40.46% · over the last 52 weeks”
“Novo Nordisk A/S (NYSE:NVO) · closed stock price · $51.22 per share · on December 30, 2025”
“Novo Nordisk A/S (NYSE:NVO) · has market capitalization · $227.595 billion”
“Baird Chautauqua International and Global Growth Fund · stated regarding · Novo Nordisk A/S (NYSE:NVO) · in its third quarter 2025 investor letter”
“Novo Nordisk A/S (NYSE:NVO) · is not on · the list of 30 Most Popular Stocks Among Hedge Funds”
“50 hedge fund portfolios · held · Novo Nordisk A/S (NYSE:NVO) · at the end of the third quarter”
“Novo Nordisk A/S (NYSE:NVO) · was held by · 45 hedge fund portfolios · in the previous quarter”
